Arrowhead Pharmaceuticals/$ARWR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Ticker
$ARWR
Sector
Primary listing
Employees
711
Headquarters
Website
ARWR Metrics
BasicAdvanced
$8.8B
-
-$0.01
1.31
-
Price and volume
Market cap
$8.8B
Beta
1.31
52-week high
$67.14
52-week low
$9.57
Average daily volume
2.4M
Financial strength
Current ratio
4.863
Quick ratio
4.728
Long term debt to equity
136.347
Total debt to equity
145.741
Interest coverage (TTM)
1.10%
Profitability
EBITDA (TTM)
122.274
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-0.20%
Operating margin (TTM)
11.86%
Effective tax rate (TTM)
41.56%
Revenue per employee (TTM)
$1,170,000
Management effectiveness
Return on assets (TTM)
4.87%
Return on equity (TTM)
8.67%
Valuation
Price to revenue (TTM)
10.429
Price to book
18.83
Price to tangible book (TTM)
19.11
Price to free cash flow (TTM)
55.136
Free cash flow yield (TTM)
1.81%
Free cash flow per share (TTM)
1.173
Growth
Revenue change (TTM)
23,258.15%
Earnings per share change (TTM)
-99.76%
3-year revenue growth (CAGR)
50.52%
10-year revenue growth (CAGR)
115.61%
3-year earnings per share growth (CAGR)
-80.60%
10-year earnings per share growth (CAGR)
-38.61%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Business Wire4 days ago
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Business Wire2 weeks ago
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $8.8B as of December 06, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of December 06, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of December 06, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.